Your cart is empty
Browse CatalogAt LarnaLabs, quality is not a marketing claim — it is the foundation of everything we do. Every research compound in our catalog undergoes a rigorous, multi-stage quality control process designed to ensure that the materials you receive meet the highest standards of purity, identity, and consistency. We understand that the integrity of your research depends on the reliability of your reagents, and we take that responsibility seriously.
Our quality assurance program encompasses the full lifecycle of every compound: from raw material sourcing and synthesis through analytical verification, documentation, cold-chain storage, and final delivery. Below is a detailed overview of each component of our quality control pipeline.
Every batch of research compound that LarnaLabs distributes passes through a defined sequence of quality gates before it is accepted into our inventory and made available for sale. No batch bypasses any stage of this pipeline, regardless of its source or prior performance history.
Every peptide batch produced for LarnaLabs undergoes High-Performance Liquid Chromatography (HPLC) analysis to verify chemical purity. We employ reversed-phase HPLC (RP-HPLC) using C18 columns with gradient elution protocols optimized for peptide separation. UV detection at 214 nm and 280 nm wavelengths allows precise quantification of the target compound relative to any synthetic impurities, deletion sequences, or degradation products.
Our analytical methods follow pharmacopeial guidelines and utilize validated protocols with established system suitability criteria including resolution, tailing factor, and theoretical plate count. Each HPLC chromatogram is reviewed by qualified analytical chemists who verify peak identification, calculate area-percent purity, and confirm that results meet our release specifications before any batch enters our inventory.
Retention time reproducibility and column performance are monitored continuously to ensure analytical consistency across production lots. Reference standards are used for peak identification, and blank injections are performed between samples to confirm the absence of carryover contamination. All chromatographic data is archived electronically with full audit trail functionality, providing a permanent record of the analytical result for each production batch.
In addition to purity testing, every compound undergoes identity verification by mass spectrometry (MS). We utilize electrospray ionization mass spectrometry (ESI-MS) and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) instruments to confirm that the observed molecular weight of each peptide matches the expected theoretical mass within established tolerance limits.
Mass spectrometry provides definitive evidence that the correct amino acid sequence has been assembled during synthesis and that no unexpected modifications — such as oxidation, deamidation, or incomplete deprotection — have occurred. Any batch showing a mass discrepancy outside of acceptable parameters is automatically rejected and does not proceed to packaging or distribution.
For peptides containing disulfide bonds or post-translational modifications, additional fragmentation analysis (MS/MS) may be performed to confirm structural integrity and correct disulfide connectivity. Tandem mass spectrometry provides sequence-level information that complements the molecular weight data from full-scan analysis, offering the highest level of identity confirmation available for complex peptide structures.
LarnaLabs maintains a strict minimum purity threshold of 97% or greater for all catalog compounds, as determined by RP-HPLC area-percent analysis. This standard exceeds the purity requirements commonly accepted in the research reagent industry and reflects our commitment to providing materials that generate reproducible, high-quality experimental data.
Many of our compounds routinely achieve purity levels of 98-99%, and the specific purity value for each batch is documented on the accompanying Certificate of Analysis. We do not blend batches to meet purity specifications — each production lot must independently meet our release criteria.
Compounds that fall below our 97% threshold during quality control testing are not released for sale under any circumstances. Failed batches are documented, root-cause analysis is performed, and corrective actions are implemented before resynthesis is initiated. The cost of maintaining this standard is absorbed entirely by us — we do not pass rejection-related expenses to customers or compromise on specifications to reduce costs.
Our contract manufacturing partners operate under Good Manufacturing Practice (GMP)-compliant protocols that govern every aspect of the production process, from raw material procurement through final packaging. These protocols establish standardized procedures for equipment calibration, environmental monitoring, personnel training, and process validation.
Key GMP-compliant practices implemented across our supply chain include:
Our manufacturing and analytical partners operate within ISO-certified facilities that meet internationally recognized standards for quality management systems. ISO certification requires documented quality management systems, regular internal and external audits, continuous improvement programs, management review processes, and full traceability of materials and processes.
Cleanroom environments used for peptide synthesis and packaging are classified according to ISO 14644 standards for airborne particulate contamination, with regular monitoring and certification to confirm ongoing compliance. These controlled environments minimize the risk of cross-contamination between production batches and protect sensitive compounds from environmental degradation during handling and packaging operations.
Peptide stability is critically dependent on proper storage conditions. LarnaLabs maintains temperature-controlled storage at -20°C for all lyophilized peptide inventory, ensuring that compounds retain their specified purity and activity from the time of manufacture through delivery to your laboratory.
Our warehouse facilities are equipped with:
In the event of any temperature excursion, affected inventory is quarantined and subjected to re-testing before being cleared for distribution. Our policy is to err on the side of product integrity — we would rather investigate and confirm compound stability than release materials whose cold chain history is uncertain.
Every order shipped by LarnaLabs includes a Certificate of Analysis (CoA) specific to the production batch from which your compound was drawn. Each CoA contains:
CoA documents are generated by our analytical laboratory and reviewed by qualified quality assurance personnel before release. Historical CoAs for previously purchased batches are available upon request through our customer support team. All analytical data supporting each CoA is archived for a minimum of five years in accordance with our data retention policies, ensuring that records are available for audit or verification long after the original order.
To provide an additional layer of confidence in our quality claims, LarnaLabs utilizes independent third-party analytical laboratories for periodic verification testing. These external laboratories operate independently from our manufacturing partners and provide unbiased confirmation of purity and identity results using their own validated methods and instrumentation.
Third-party testing activities include:
Results from third-party testing are systematically compared against our internal analytical data to verify inter-laboratory agreement and confirm the accuracy and reliability of our quality control program. Any discrepancies trigger a formal investigation and are fully resolved before the affected products are released or remain in distribution. Third-party testing reports are available upon request for applicable batches.
LarnaLabs operates a strict zero-tolerance policy on quality control failures. Any batch that fails to meet our release specifications — whether for purity, identity, physical appearance, documentation completeness, or any other quality attribute — is rejected in its entirety. Rejected batches are segregated, clearly labeled to prevent inadvertent release, and disposed of according to applicable environmental regulations.
Upon rejection, a formal deviation investigation is initiated to determine the root cause of the failure. Whether the cause is traced to raw material quality, synthesis parameters, purification performance, or analytical methodology, appropriate corrective and preventive actions are implemented before resynthesis is authorized. This rigorous approach to failure management ensures that quality problems are systematically eliminated rather than simply worked around.
The cost and time required for rejection investigations and resynthesis are absorbed entirely by LarnaLabs and our manufacturing partners. Customers never receive substituted, blended, or out-of-specification materials, and delivery timelines affected by quality failures are managed proactively through customer communication and inventory management.
Every compound distributed by LarnaLabs is assigned a unique batch/lot number that enables complete forward and reverse traceability throughout our supply chain. From raw amino acid procurement through synthesis, purification, lyophilization, quality testing, packaging, and shipment, every step is documented and linked to the batch identifier.
Our batch tracking system allows us to:
This traceability infrastructure is not merely an internal administrative tool — it is a fundamental quality commitment that enables us to stand behind every product we distribute with complete confidence in its documented history.
LarnaLabs stands behind the quality of every product we ship. If any compound does not meet the specifications stated on its Certificate of Analysis, we will replace it or issue a full refund — no questions asked. Our reputation is built on the trust researchers place in our materials, and we are committed to earning that trust with every order.
